Australian biopharmaceutical company Immuron Limited is making waves in the industry, with its focus on research, development, and commercialization of polyclonal antibodies. The company boasts operations across Australia, Israel, Canada, the United States, and beyond. With a clear segmentation into Research and Development, as well as Hyperimmune Products, Immuron Limited offers a range of products to support overall digestive health and gastrointestinal protection. Their flagship product, Travelan, is an over-the-counter medicine that helps to reduce the risks of travelers' diarrhea and minor gastrointestinal disorders. The company is also developing Travelan and IMM-529 to combat clostridium difficile and traveler's diarrhea, respectively. Additionally, Immuron has a research agreement with the Naval Medical Research Center and a collaboration agreement with the Walter Reed Army Institute of Research to develop therapies for various conditions. Incorporated in 1994 and based in Carlton, Australia, Immuron Limited is at the forefront of biopharmaceutical innovation.
Immuron Limited's ticker is IMRN
The company's shares trade on the NASDAQ stock exchange
They are based in Melbourne, Australia
There are 11-50 employees working at Immuron Limited
It is https://www.immuron.com.au/
Immuron Limited is in the Healthcare sector
Immuron Limited is in the Biotechnology industry
The following five companies are Immuron Limited's industry peers: